tbuckley/cabot-search huggingface dataset:
New osteoporosis therapies appear closer
Authors: A. Skolnick
Journal: JAMA (1990)

PROGRESS toward the development of new therapies for osteoporosis was reported at the Second International Conference on Research Advances in Osteoporosis, in Arlington, Va, sponsored by the National Osteoporosis Foundation, the American Society for Bone and Mineral Research, and the National Institutes of Health. Among the treatments showing promise in clinical trials are diphosphonates and a nasal-spray form of calcitonin. Preliminary findings from a yet unpublished study, suggesting that a new, combined hormone therapy may actually increase spinal bone density in osteoporotic women, also were reported. While calcitonin-salmon (Calcimar, manufactured by Rorer Pharmaceuticals, Fort Washington, Pa) is currently approved for the treatment of established osteoporosis where estrogen is contraindicated, it is not used for prevention because it requires regular injections. In a controlled study conducted by Claus Christiansen, MD, Glostrup (Denmark) Hospital, involving 37 women with established postmenopausal osteoporosis, a new, nasal-spray form of the drug has been shown to
Changing treatment of breast cancer in New Mexico from 1969 through 1985
Authors: B. A. Mann
Journal: JAMA (1988)

A review of information from the New Mexico Tumor Registry on women diagnosed as having primary breast cancer from 1969 through 1985 revealed temporal changes in the surgical treatment of this disease. After 1980 the percentage of women receiving breast-conserving surgery for local-stage disease increased from 6% to 25%. Most surgeons performing operations for breast cancer had not performed a breast-conserving operation before 1981 but had used this procedure at least once in the period from 1981 through 1985. Women younger than 50 years or older than 80 years were most likely to undergo this procedure. In that period, radiotherapy after breast-conserving surgery could not be documented for 26% of the women 65 years old or younger or for 56% of the women aged 65 years or older. Thus, there has been a marked shift in New Mexico in the surgical approach to local-stage breast cancer in the 1980s. This shift involved most surgeons treating the disease and included women of all age groups. The apparent lack of adjuvant radiotherapy in some women receiving conservative surgeries may prove to be a deleterious consequence of this change in surgical management. (<i>JAMA</i>1988;259:3413-3417)
Effects of Spinal Osteomyelitis on Porphyrin-Precursor Excretion, and the Presence of Gout in a Patient with Latent Acute Intermittent Porphyria
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Pilot Study Examining Changes in Dust Lead Loading on Walls and Ceilings after Lead Hazard Control Interventions
Authors: Ellen Tohn, Sherry Dixon, Ron Rupp, Scott Clark
Journal: Environmental Health Perspectives (2000)

The U.S. Department of Housing and Urban Development (HUD) guidelines on lead hazard control instruct contractors to clean floors, windows, walls, ceilings, and other horizontal surfaces to remove lead-contaminated dust and debris after lead interventions are conducted. This dust removal activity adds costs to each project. The need to clean floors and windows is well documented in the HUD guidelines. However, there is substantially less documentation to support the recommendation to clean walls and ceilings. We examined whether it is necessary to clean walls and ceilings after lead hazard control (LHC) interventions by comparing dust lead loadings measured on these surfaces before an LHC intervention to dust lead loadings after the intervention. Twenty-two dwelling units undergoing substantial LHC measures consistent with the HUD guidelines were enrolled in the study. There was a significant increase in dust lead loading on walls and ceilings between the pre- and postintervention. The change in wall dust lead loading was substantial and created potentially harmful lead exposures. Although statistically significant, the change in ceiling dust lead loading was minimal and the postintervention dust lead loadings were far below the existing federal floor dust lead clearance standard. These results strongly support the recommendations in the HUD guidelines to clean walls after LHC interventions and do not provide sufficient justification to alter the current recommendation to clean ceilings after lead work.
Casual Relationships.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erythropoietin To Prevent Blood Transfusion in Patients Having Total Hip Replacement Surgery
Journal: Annals of Internal Medicine (2000)

Summaries for Patients5 December 2000Erythropoietin To Prevent Blood Transfusion in Patients Having Total Hip Replacement SurgerySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-11-200012050-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Patients can lose enough blood during hip replacement surgery to require blood transfusions. Transfusions of blood from other people always carry a small risk for infection or transfusion reactions. Transfusion of blood donated by the patient before surgery (predonation) avoids many of these problems; however, it is inconvenient, and many patients have medical conditions that prevent them from predonating blood. Erythropoietin is a protein made by the kidney that stimulates the bone marrow to make red blood cells. It is also manufactured as a drug called epoetin alfa. ... Author, Article, and Disclosure InformationThe summary below is from the full report titled “Erythropoietin with Iron Supplementation To Prevent Allogeneic Blood Transfusion in Total Hip Joint Arthroplasty. A Randomized, Controlled Trial.” It is in the 5 December 2000 issue of Annals of Internal Medicine (volume 133, pages 845-854). The authors are BG Feagan, CJ Wong, A Kirkley, DWC Johnston, FC Smith, P Whitsitt, SL Wheeler, and CY Lau.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoErythropoietin with Iron Supplementation To Prevent Allogeneic Blood Transfusion in Total Hip Joint Arthroplasty Brian G. Feagan , Cindy J. Wong , Alexandra Kirkley , D.W.C. Johnston , Frank C. Smith , Paul Whitsitt , Susan L. Wheeler , and Catherine Y. Lau Metrics 5 December 2000Volume 133, Issue 11Page: I-55KeywordsBlood countsBlood transfusionErythropoietinHipRed blood cellsSurgeryThromboembolismTotal hip arthroplastyTotal hip replacementTransfusion medicine ePublished: 5 December 2000 Issue Published: 5 December 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Shared Sacrifice
Authors: Joseph T. Painter
Journal: JAMA (1994)

In a February 1993<i>JAMA</i>Editorial, leaders of the American Medical Association (AMA) wrote: "We stand at a watershed. The opportunity for physicians to do what is best for our patients in the public policy arena has never been better. Within our grasp is the chance to open the door to appropriate care for every child and adult, to see that every health dollar is invested in care that is right for every patient; to end outrageous administrative costs and wasteful paperwork; and to guarantee all patients the freedom to choose their own physician."<sup>1</sup>This statement sounds remarkably similar to the speech President Clinton made to Congress on September 22, 1993; the AMA has been calling for security, savings, simplicity, quality, choice, and responsibility since 1990 with the unveiling of its Health Access America<sup>2,3</sup>proposal. Yet in that same Editorial, AMA leaders wrote, "But as our new president
AN AID IN THE DIAGNOSIS OF TUMOR OF THE URINARY BLADDER
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SULFADIAZINE
Authors: W. H. B.
Journal: Annals of Internal Medicine (1942)

Editorial1 December 1942SULFADIAZINEW. H. B.W. H. B.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-17-6-1029 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptLess than eight years ago Domagk published his initial report on the striking effects of the brick-red dye prontosil in experimental hemolytic streptococcal infections in mice. Shortly thereafter it was found that a relatively simple chemical compound, sulfanilamide, or para-amino-benzene-sulfonamide, was the active constituent of prontosil. These discoveries marked the dawn of a new era in the chemotherapy of bacterial infections. As a result a stupendous amount of experimental work has been carried out and the medical literature has been flooded with articles on the effects of the various sulfonamides in the treatment of infectious diseases. Many new compounds have...1 RICH AR: The rôle of hypersensitivity in periarteritis nodosa as indicated by 7 cases developing during serum sickness and sulfonamide therapy, Bull. Johns Hopkins Hosp., 1942, lxxi, 123-140. Google Scholar2 LONG PH: Personal communication to the author. Google Scholar3 FINLANDPETERSONGOODWIN MOLRA: Sulfadiazine: further clinical studies of its efficacy and toxic effects in 460 patients, ANN. INT. MED., 1942, xvii, 920-934. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1942Volume 17, Issue 6Page: 1029-1032KeywordsChemotherapyInfectious diseasesStreptococcal infectionsSulfonamide ePublished: 1 December 2008 Issue Published: 1 December 1942 PDF downloadLoading ...
Transplantation
Authors: Thomas E. Starzl
Journal: JAMA (1986)

Nineteen eighty-five and 1986 have been consolidation years in which the great advances of the early 1980s were brought closer to fruition. The single most important advance is the immunosuppressive agent, cyclosporine, which was developed by Borel et al.<sup>1</sup>Clinical trials with this agent were begun in England by Calne et al<sup>2</sup>in 1978 and a year later in the United States.<sup>3</sup>The drug was released by the Food and Drug Administration for general use in November 1983. Most commonly, cyclosporine is used in combination with steroids.<sup>3</sup> The effectiveness of cyclosporine precipitated an avalanche of cadaveric transplantations of a variety of organs, beginning in 1980 and continuing to the present. Cadaveric renal transplantation has become increasingly accepted, not only because the results are improved over those with old-style immunosuppression, but also because the quality of life is so much better. With cyclosporine, dosage of the steroid
Patient-reported outcomes for determining prognostic groups in veterans with stage IV solid tumors starting systemic therapy.
Authors: Victor Tsu-Shih Chang, Charles B. Scott, Melanie L. Gonzalez, Jan Einhorn, Houling Yan, Maryann Sullivan, Shanti Srinivas, Fengming Zhong, Barbara Crump, Emma R Paz-Querubin, Monica McPherson, Celeste DeMarco, Basil Kasimis
Journal: Journal of Clinical Oncology (2014)

48 Background: A Recursive Partitioning Analysis (RPA) prognostic algorithm based on quality of life and symptoms predicted 4 groups with distinct median survivals in patients with metastatic solid tumors receiving chemotherapy (ASCO 2013, Abst 9567). We update our findings. Methods: The RPA algorithm is based upon Karnofsky performance status (KPS), Functional Assessment of Cancer Therapy (FACT) physical well-being (PWB) subscale, and Memorial Symptom Assessment Scale Short Form (MSAS-SF) physical symptom distress (PHYS) subscale. Starting in 2007, a convenience sample of Veterans who were prescribed systemic treatment for their cancer was enrolled in an IRB approved protocol, and completed quality of life (FACT- G) and symptom (MSAS SF) questionnaires at the first cycle of treatment. We analyzed records of patients with stage IV metastatic solid tumors enrolled through June 2013, and determined survival as of June 15, 2014. Analyses were performed with STATA 11.0. Results: There were 97 patients(pts). The median age was 64 yrs, range 27-88. Males comprised 95 (98%) pts. First line chemotherapy was given to 78 (80%) pts. The most common primary sites were lung cancer 33 (35%), prostate 17 (17%) and colon 11 (11%) pts. Median KPS was 90% range 40-100%, PWB median 23 (range 6-28), and MSAS SF median PHYS 0.76 (range 0-3.2). Overall median survival was 285 days (range 6-2,358) and 80 pts (82%) had died. There was 1 pt in group 1, 58 in group 2, 12 in group 3, and 23 in group 4. The patient in group 1 had uterine sarcoma. Median survival (days) by RPA group was 155 for group 1, 177 for group 2, 292 for group 3, and 674 for group 4 (p=.011). Conclusions: These preliminary findings suggest that this algorithm is capable of dividing patients with metastatic solid tumor who are starting systemic therapy into prognostic groups. Further development is indicated.
Serologic Tests in the Diagnosis of Infectious Diseases
Authors: John C. Ayres, Roy F. Feemster
Journal: New England Journal of Medicine (1950)

GREAT advances have been made of late in the diagnosis, control and treatment of infectious diseases through the combined efforts of practicing physicians, laboratory workers and public-health workers. Foremost among these advances have been the development and standardization of laboratory diagnostic procedures, which are being used routinely. However, some procedures are still so highly specialized that competent technicians are required for their satisfactory performance. This, coupled with the high cost and scarcity of reagents, makes it prohibitive for most laboratories to offer these procedures as a routine service. For instance, the isolation and identification of virus and rickettsial agents are . . .
Correction to: Trends in clinical profiles, organ support use and outcomes of patients with cancer requiring unplanned ICU admission: a multicenter cohort study
Authors: Fernando G. Zampieri, Thiago G. Romano, Jorge I. F. Salluh, Leandro U. Taniguchi, Pedro V. Mendes, Antonio P. Nassar, Roberto Costa, William N. Viana, Marcelo O. Maia, Mariza F. A. Lima, Sylas B. Cappi, Alexandre G. R. Carvalho, Fernando V. C. De Marco, Marcelo S. Santino, Eric Perecmanis, Fabio G. Miranda, Grazielle V. Ramos, Aline R. Silva, Paulo M. Hoff, Fernando A. Bozza, Marcio Soares
Journal: Intensive Care Medicine (2020)
Antihistamines and Driving Performance
Journal: Annals of Internal Medicine (2000)

Summaries for Patients7 March 2000Antihistamines and Driving PerformanceSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-5-200003070-00028 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Many people take medications for allergy symptoms. Some of these medications, particularly the older nonprescription antihistamines, can cause drowsiness. It is generally known that driving while drowsy can be unsafe. However, the influence of antihistamines on driving performance has not been studied in detail.Why did the researchers do this particular study?The researchers wanted to determine exactly how much two common antihistamines affect driving performance. One antihistamine was diphenhydramine (Benadryl), an older drug known to cause drowsiness. The other was a newer drug, fexofenadine (Allegra), which is ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Effects of Fexofenadine, Diphenhydramine, and Alcohol on Driving Performance. A Randomized, Placebo-Controlled Trial in the Iowa Driving Simulator.”. It is in the 7 March 2000 issue of Annals of Internal Medicine (volume 132, pages 354-363). The authors are J.M. Weiler, J.R. Bloomfield, G.G. Woodworth, A.R. Grant, T.A. Layton, T.L. Brown, D.R. McKenzie, T.W. Baker, and G.S. Watson.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEffects of Fexofenadine, Diphenhydramine, and Alcohol on Driving Performance John M. Weiler , John R. Bloomfield , George G. Woodworth , Angela R. Grant , Teresa A. Layton , Timothy L. Brown , David R. McKenzie , Thomas W. Baker , and Ginger S. Watson Metrics 7 March 2000Volume 132, Issue 5Page: 354KeywordsAlcoholsAllergy and immunologyAntihistaminesDrugsSimulation and modeling ePublished: 15 August 2000 Issue Published: 7 March 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
Diethylstilbestrol
Authors: Melvin A. Benarde
Journal: JAMA (1972)

<h3>To the Editor.—</h3> I suspect it's only oversight, but on several occasions recently, I've noticed an error that creeps into the literature. Dr. Bongiovanni (<b>219</b>:1340, 1972) referred to diethylstilbestrol as "this steroidal hormone" some three times in his letter. Although diethylstilbestrol has hormonal activity, it is a nonsteroidal estrogen.
Targeting Hemophilia
Authors: Tracy Hampton
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Culture of normal human leukocytes
Authors: G. E. Moore
Journal: JAMA (1967)

Rapidly growing and apparently permanent cultures were established from hematopoietic cells from two staff members with no known malignant disease. The cell lines were similar to those derived from leukocytes from the peripheral blood of patients with malignancies of either hematopoietic or nonhematopoietic origin and to the lymphoblastoid cell lines derived from Burkitt's lymphoma. Both cell lines contained a herpetic-like virus (leukovirus), produced immunoglobulins, and grew rapidly in various suspension cultures.